SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Manny Gugliuzza who wrote (357)4/6/1998 5:18:00 PM
From: Easy Mark  Read Replies (1) of 1510
 
Top ten reasons to be long IMNR:
1. Remune has a probability-weighted value 5x current IRC stock price assuming standard rates of success.
2. Investment community got burned by IRC in 1992/1994 - thus negative sentiment may be overdone.
3. The RA, psoriasis, and cancer technologies are potentially bigger than Remune.
4. IRC has bent over backwards to meet FDA requirements for Phase III design and data analysis.
5. Multiple independent Remune trials are underway - not just company financing.
6. Patent protection is as well done as possible.
7. Manufacturing pipeline is in place.
8. Insiders have put their own money on the line.
9. A scientifically verifiable theory for the mechanism of effect for Remune is now available.
10. Remune has a ten-year history establishing safety both alone and in combination with antiviral drugs.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News